Your Cart Is Empty!
There are an estimated 5.3 million Americans with Alzheimers disease (AD), a number that is expected to grow as the Baby Boomers continue to age, which explains why drugmakers have not shied away from the space despite what an academic group recently estimated is a staggering 99.6-percent failure rate for compounds that have entered human testing.
The annual Alzheimers Association International Conference is being held this week in Washington D.C., and will host the unveiling of new data for several high-profile members of the newest wave of Alzheimers disease therapies, including Biogens aducanumab and Axovants RVT-101.
The two products are very different in both form and function, as aducanumab is a mAb that targets beta-amyloid and is believed to have disease-modifying potential, whereas RVT-101 is a small molecule that antagonises the 5-HT6 serotonin receptor antagonist and is thought capable of offering a modest benefit by delaying the cognitive decline associated with AD.
Whats more, the two have captured the attention of investors for different reasons as well, as Biogens programme is the latest would-be contender seeking to prove the often maligned "amyloid hypothesis" for explaining the pathogenesis of AD, while Axovant raised eyebrows by completing a massive $315-million IPO based solely on the prospects for RVT-101, a compound that the company bought only months prior for $5 million after it had been shelved by GlaxoSmithKline.
Data expected to be unveiled by Biogen on July 22 have generated the most discussion going into this weeks meeting, as observers are anxious to see how effective a 6 mg/kg dose of aducanumab will be and - importantly - whether it will prove safer than a 10 mg/kg dose, which proved remarkably effective but may be hamstrung by a high rate (41 percent) of amyloid related imaging abnormality (ARIA) events. (See ViewPoints: Ballyhooed safety data for Biogens aducanumab coming next week - important or nah?)
As for Axovant, this weeks readouts should likely prove less of an inflection point as the two scheduled presentations will involve discussions of completer and responder analyses from previously reported studies of RVT-101.
To gain better understanding about the views of doctors on the how recent events are shaping their perspective on AD as well as how these new agents may ultimately fit into the treatment algorithm, FirstWord PLUS is polling US- and/or EU5-based neurologists and asking them
- According to results from a Phase Ib study, Alzheimers patients receiving monthly 10 mg/kg doses of aducanumab (mAb against beta-amyloid) achieved a 71-percent reduction in cognitive decline on the CDR-SB test. However, 41 percent of patients had amyloid related imaging abnormality (ARIA) events, including 55 percent of ApoE4 carriers and 35 percent of ApoE4 non-carriers. Assuming this risk/benefit is similar in Phase III testing, to whom would you typically prescribe aducanumab?
- Assuming safety and efficacy data for a 6 mg/kg dose of aducanumab (to be presented on July 22) line up in between the 3 mg/kg and 10 mg/kg doses, how would that influence your belief in the "amyloid hypothesis" for Alzheimers pathogenesis?
- Assuming safety and efficacy data for a 6 mg/kg dose of aducanumab line up in between the 3 mg/kg and 10 mg/kg doses, with its efficacy on measures like the CDR-SB test barely achieving significance while causing less ARIA events than 10 mg/kg, would you be more likely to prescribe 6 mg/kg or 10 mg/kg dose of aducanumab?
- Assuming one or more small molecule 5-HT6 serotonin receptor antagonists are approved over the next few years, describe your level of enthusiasm for prescribing an agent that offers a modest delay in cognitive decline when used as adjunct to donepezil but an expensive (branded) price tag?
- There are two small molecule 5-HT6 serotonin receptor antagonists in late-stage development, including idalopirdine (from Lundbeck/Otsuka) and Axovants RVT-101. Assuming they both are approved as adjunct to donepezil based on similar efficacy profiles, what will be the most important criteria for deciding which to prescribe?
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.